Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851681)
Watch
English
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen
scientific article
Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
22034911
retrieved
13 November 2016
title
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen
(English)
1 reference
stated in
PubMed
PubMed ID
22034911
retrieved
13 November 2016
main subject
crizotinib
1 reference
based on heuristic
inferred from title
author name string
Sen Zhang
series ordinal
1
0 references
Frank Wang
series ordinal
2
0 references
Jeffrey Keats
series ordinal
3
0 references
Xiaotian Zhu
series ordinal
4
0 references
Yaoyu Ning
series ordinal
5
0 references
Scott D Wardwell
series ordinal
6
0 references
Lauren Moran
series ordinal
7
0 references
Qurish K Mohemmad
series ordinal
8
0 references
Rana Anjum
series ordinal
9
0 references
Yihan Wang
series ordinal
10
0 references
Narayana I Narasimhan
series ordinal
11
0 references
David Dalgarno
series ordinal
12
0 references
William C Shakespeare
series ordinal
13
0 references
Juan J Miret
series ordinal
14
0 references
Tim Clackson
series ordinal
15
0 references
Victor M Rivera
series ordinal
16
0 references
publication date
December 2011
0 references
published in
Chemical Biology and Drug Design
0 references
volume
78
0 references
page(s)
999-1005
0 references
issue
6
0 references
cites work
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Activating mutations in ALK provide a therapeutic target in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
20 March 2017
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
Inhibition of ALK signaling for cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
Oncogenic mutations of ALK kinase in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
29 September 2017
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265718
retrieved
2 June 2018
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1111%2FJ.1747-0285.2011.01239.X
retrieved
21 January 2018
Identifiers
DOI
10.1111/J.1747-0285.2011.01239.X
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1902986
OpenCitations bibliographic resource ID
1902986
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1902986
PMCID
3265718
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1902986
PubMed ID
22034911
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1902986
ResearchGate publication ID
51754366
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
